Trial Outcomes & Findings for A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites (NCT NCT01722994)

NCT ID: NCT01722994

Last Updated: 2016-03-02

Results Overview

All subjects will be examined 1 week and 3 weeks after the wounds are closed with absorbable suture to assess the presence or absence of scarring. A scale of 0-1 was used (0=absent; 1=present).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

97 participants

Primary outcome timeframe

1 week

Results posted on

2016-03-02

Participant Flow

Participant milestones

Participant milestones
Measure
Group 1 Punch Biopsy Wound Using Chromic Gut Suture
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound Using Polyglactin 910 Suture
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Overall Study
STARTED
49
48
Overall Study
COMPLETED
24
31
Overall Study
NOT COMPLETED
25
17

Reasons for withdrawal

Reasons for withdrawal
Measure
Group 1 Punch Biopsy Wound Using Chromic Gut Suture
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound Using Polyglactin 910 Suture
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Overall Study
Missing data
25
17

Baseline Characteristics

A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1 Punch Biopsy Wound Using Chromic Gut Suture
n=49 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound Using Polyglactin 910 Suture
n=48 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Total
n=97 Participants
Total of all reporting groups
Age, Customized
18 years and older
49 participants
n=5 Participants
48 participants
n=7 Participants
97 participants
n=5 Participants
Sex/Gender, Customized
Not collected
49 participants
n=5 Participants
48 participants
n=7 Participants
97 participants
n=5 Participants
Region of Enrollment
United States
49 participants
n=5 Participants
48 participants
n=7 Participants
97 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 week

Population: Of the 97 subjects who enrolled, 49 had punch biopsy site closure with chromic gut and 48 with polyglactin 910 sutures. 42 subjects were lost to follow-up or had missing data. Of the 55 subjects who completed the study - 24 received chromic gut and 31 received polyglactin 910.

All subjects will be examined 1 week and 3 weeks after the wounds are closed with absorbable suture to assess the presence or absence of scarring. A scale of 0-1 was used (0=absent; 1=present).

Outcome measures

Outcome measures
Measure
Group 1 Punch Biopsy Wound
n=24 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound
n=31 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Presence of Scarring
1 participants
1 participants

PRIMARY outcome

Timeframe: 3 weeks

Population: Of the 97 subjects who enrolled, 49 had punch biopsy site closure with chromic gut and 48 with polyglactin 910 sutures. 42 subjects were lost to follow-up or had missing data. Of the 55 subjects who completed the study - 24 received chromic gut and 31 received polyglactin 910.

All subjects will be examined 1 week and 3 weeks after the wounds are closed with absorbable suture to assess the presence or absence of scarring. A scale of 0-1 was used (0=absent; 1=present).

Outcome measures

Outcome measures
Measure
Group 1 Punch Biopsy Wound
n=24 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound
n=31 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Presence of Scarring
0 participants
1 participants

SECONDARY outcome

Timeframe: 3 weeks

Population: Of the 97 subjects who enrolled, 49 had punch biopsy site closure with chromic gut and 48 with polyglactin 910 sutures. 42 subjects were lost to follow-up or had missing data. Of the 55 subjects who completed the study - 24 received chromic gut and 31 received polyglactin 910.

The time post placement when the suture fell out.

Outcome measures

Outcome measures
Measure
Group 1 Punch Biopsy Wound
n=24 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound
n=31 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Length of Time Till Absorbable Suture Fall Out
15.7 Days
Standard Deviation 6.9
20.2 Days
Standard Deviation 4.2

SECONDARY outcome

Timeframe: 1 week

Population: Of the 97 subjects who enrolled, 49 had punch biopsy site closure with chromic gut and 48 with polyglactin 910 sutures. 42 subjects were lost to follow-up or had missing data. Of the 55 subjects who completed the study - 24 received chromic gut and 31 received polyglactin 910.

Any infected wounds were documented. A scale of 0-1 was used (0=absence; 1= present).

Outcome measures

Outcome measures
Measure
Group 1 Punch Biopsy Wound
n=24 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound
n=31 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Presence of Infection
4 participants
1 participants

SECONDARY outcome

Timeframe: 3 weeks

Population: Of the 97 subjects who enrolled, 49 had punch biopsy site closure with chromic gut and 48 with polyglactin 910 sutures. 42 subjects were lost to follow-up or had missing data. Of the 55 subjects who completed the study - 24 received chromic gut and 31 received polyglactin 910.

Any infected wounds were documented. A scale of 0-1 was used (0=absence; 1= present).

Outcome measures

Outcome measures
Measure
Group 1 Punch Biopsy Wound
n=24 Participants
One of two absorbable sutures is used to close punch wounds. Chromic Gut Sterile absorbable Suture (Ethicon)
Group 2 Punch Biopsy Wound
n=31 Participants
This is one of two absorbable sutures used to close punch biopsy wounds. Polyglactin 910 sterile synthetic absorbable suture (Ethicon): Half of punch biopsy wounds are closed with each absorbablesuture
Presence of Infection
1 participants
0 participants

Adverse Events

Group 1 Punch Biopsy Wound

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 Punch Biopsy Wound

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Robert Brodell

University of Mississippi Medical Center

Phone: 601-815-8000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place